Analysis of the effectiveness of cefdinir in the treatment of acute purulent osteomyelitis in children

Authors: T.V. Marushko, Doctor of Medical Sciences, Professor, T.V. Kurilina, Doctor of Medical Sciences, Professor, S.A. Akimovich

National University of Health of Ukraine named after. P.L. Shupyk, KNP KGDKB No. 1, Kyiv


The diagnosis of HGO is established in accordance with the diagnostic criteria developed by the Society of Pediatric Infectious Diseases and the Society of Infectious Diseases of America – recommendations for the diagnosis and treatment of HGO in pediatrics (2021) [4]. In order to optimize treatment and improve prognosis, experts suggested switching antibiotic treatment from parenteral administration to oral administration of antibacterial drugs in a shorter and earlier period. The decision to switch to oral antibiotics depends on the disappearance of symptoms of fever, intoxication, improvement in physical condition and a decrease in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

The optimal oral drug should have a spectrum of action comparable to the parenteral one, due to which the child showed clinical and laboratory improvement [4, 8, 11].

Recently developed safety guidelines for the use of early stepwise antibiotic treatment (transition from parenteral to oral) have influenced the clinical practice of treating bone infections in our hospital.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design